Cannabis is the most commonly used illicit drug in the United States, and its use is
associated with rates of development of abuse and dependence, treatment admission and relapse
that are comparable to other illicit drugs. Currently there is no effective pharmacological
treatment for cannabis-use disorders. The purpose of the present study is to evaluate the
ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a
medication for cannabis-use disorders.